death from semaglutide FDA Approves to Reduce Kidney Disease, Cardiovascular Risk in Adults With Type 2 Diabetes, Chronic Kidney Disease Effects of Semaglutide on Heart
Description
Conclusion The discovery of GLP-1 agonists' potential in treating chronic kidney disease is an exciting development in medical research
References Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, et al
The Centers for Medicare & Medicaid Services has selected semaglutide for price negotiation
What it can do is improve the conditions for fat loss by stabilizing blood sugar, reducing inflammation, and supporting liver function
Data from clinical trials don't suggest a causal relationship between the drug and NAION, it added
doi: 10.1038/s41467-021-21962-2, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 70
